360 ONE WAM LIMITED received regulatory approvals from SEBI and Stock Exchanges to rename its subsidiary Batlivala & Karani Securities to 360 ONE Capital Market Private Limited. The entity will continue its stock broking and research analyst operations under the new name with existing registration numbers.
Banaras Beads Limited obtained a 'One Star Export House' Certificate of Recognition from the Ministry of Commerce and Industry, DGFT. Valid for five years from February 18, 2026, to February 18, 2031, this status recognition enhances the company's export credentials and operational standing in international markets.
Sat Kartar Shopping Limited has received formal approval from the National Stock Exchange of India to change its name to Sat Kartar Life Limited. The name change is effective in exchange records from April 23, 2026.
OneSource Specialty Pharma Limited received the renewal of EU-GMP certification for its flagship Unit II manufacturing facility in Bengaluru. The certification follows a successful inspection by European regulatory authorities. This renewal validates the site's capabilities in biologics drug-substance and sterile injectable manufacturing for the European market.
Aurobindo Pharma received USFDA final approval for Dextromethorphan Polistirex Extended-Release Oral Suspension (OTC). The product, bioequivalent to Delsym, has an estimated annual market size of ₹1,283.4 Crore ($138M). Manufacturing will occur at the APL Healthcare Unit-IV facility with a planned launch in Q2FY27.
Cipla Limited announced the conclusion of a routine cGMP and Pre-Approval Inspection by the USFDA at its Goa facility. The inspection, conducted from April 6-17, 2026, resulted in two inspectional observations in Form 483. The company is committed to addressing these observations within the stipulated timeframe.
Zen Technologies received an arms manufacturing licence from the Government of India to produce 12.7mm, 23mm, 30mm, and 40mm cannons. This approval enables the company to manufacture critical weapon systems for Air Defence and Counter-Drone roles, strengthening its position in India's indigenous defence ecosystem under the IDDM framework.
Morepen Laboratories successfully cleared a USFDA inspection at its Masulkhana, Himachal Pradesh API facility with zero observations (NIL Form 483). This marks the company's fourth consecutive successful inspection over eight years. The clearance reinforces Morepen's quality compliance for exporting APIs to regulated markets including the US and Europe.
Apollo Micro Systems Limited received a lifetime Arms Manufacture License from the Government of India. This authorizes the company to manufacture high-value strategic weapon systems, including missiles and torpedoes, at its Hyderabad facilities. This grant transforms the company into an end-to-end platform manufacturer for the Indian Armed Forces and export markets.
AGI Infra Limited received a key license from the Jalandhar Development Authority for its 'AGI Green Crest' housing project. The project involves developing 452 residential units (3BHK and 2BHK) in Jalandhar. The approval is valid until March 2031 and is expected to enhance the company's revenue and profitability through flat sales.
Aurobindo Pharma received final USFDA approval for Glycerol Phenylbutyrate Oral Liquid, 1.1 g/mL. The product, bioequivalent to Ravicti, targets a US$ 50.2 million (₹466.86 Crore) market. Manufacturing will occur at the company's Unit-III facility with an immediate commercial launch planned to treat urea cycle disorders.
KPI Green Energy Limited has been granted an Inter-State Power Trading Licence (Category IV) by the CERC. Combined with its existing intra-state license, this approval enables the company to establish a pan-India power trading platform. This strategic development enhances flexibility in power sales and supports better price discovery across India's national power markets.
Zydus Lifesciences Limited received the Establishment Inspection Report (EIR) and approval from the USFDA for its oncology injectable facility in SEZ1, Ahmedabad. The approval follows a Pre-Approval Inspection conducted in November 2025 for a new isolator injectable line. This regulatory milestone clears the path for commercial manufacturing at the site.
Alembic Pharmaceuticals Limited received USFDA final approval for Methotrexate Injection USP in multi-dose and single-dose vials. The drug is indicated for neoplastic diseases, rheumatoid arthritis, and severe psoriasis. This marks the company's 236th ANDA approval, strengthening its generic injectable portfolio in the US market.
Jeena Sikho Lifecare Limited received NABH accreditation for its Noida Hospital for Panchakarma services. The certification (AH-2026-0451) is valid until March 09, 2029. This accreditation signifies adherence to national quality standards for healthcare delivery and patient safety without constituting a business expansion or acquisition.
Shriram Finance Ltd's subsidiary, Shriram Overseas Investments Limited, received in-principle approval from the RBI to commence Primary Dealer (PD) business. This regulatory authorization allows the group to expand its financial services footprint into the primary dealer segment, subject to fulfillment of specified conditions.
Shriram Finance's wholly owned subsidiary, Shriram Overseas Investments Limited, received in-principal approval from the RBI to commence Primary Dealer (PD) business. This approval is subject to specified compliance conditions and follows an earlier intimation from March 2026.
Tembo Global Industries' subsidiary, Tembo Classic Engineering Private Limited, has received a government licence for ammunition manufacturing from the Ministry of Home Affairs. This regulatory approval enables the company to commence production of various caliber ammunition, marking a significant milestone in its strategic expansion into India's defence and security manufacturing sector.
Tembo Global Industries subsidiary, Tembo Classic Engineering, has been granted a license by the Ministry of Home Affairs to manufacture ammunition of various calibers. This significant milestone enables the group to enter the defense and security manufacturing sector. The company is prepared to begin commercial production for arms and ammunition as per its schedule.
Satin Creditcare Network Limited's wholly owned subsidiary, Satin Growth Alternatives Limited (SGAL), has received SEBI registration as a Category II Alternative Investment Fund. The registration, granted on April 13, 2026, aligns with the group's business objectives and remains valid until the fund is wound up.
Ujjivan Small Finance Bank reported that the RBI returned its application for transition to a Universal Bank. The regulator advised the bank to demonstrate a more diversified loan portfolio before reapplying. The bank plans to consider a fresh application after further progress in portfolio diversification.
Indoco Remedies Limited announced that the U.S. FDA successfully completed a Pre-Approval Inspection at its testing facility in Chhatrapati Sambaji Nagar (Aurangabad). The inspection, conducted from April 08-10, 2026, concluded with zero Form 483 observations, confirming compliance with regulatory standards.
Vraj Iron and Steel Limited received regulatory approval for electricity duty exemption on power generated from its captive solar plant at the Siltara Division. Effective from December 17, 2025, this exemption is expected to significantly reduce energy costs and improve operating margins. The approval supports the company's long-term sustainability and renewable energy initiatives.
Execution
Effective from December 17, 2025 and remains valid till the solar power plant is operational for auxiliary use
Piramal Pharma Limited successfully closed its US FDA inspection at its Lexington, USA manufacturing facility. The US FDA issued an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) classification. This marks the formal and successful conclusion of the inspection initiated in December 2025.
Coforge Limited has secured all unconditional regulatory and statutory clearances for its acquisition of Encora. The transaction is on track to close by the end of April 2026, creating a combined entity with a ₹23,250.0 Crore ($2.5B) run rate. This acquisition significantly scales Coforge's AI-led engineering and cloud services capabilities.
Shalby Ltd's Krishna unit in Ahmedabad received regulatory approval to perform Kidney Transplants for five years, effective April 9, 2026. This milestone enables the facility to offer comprehensive, life-saving local transplant services, enhancing continuity of care and reducing travel needs for patients in the surrounding community.
Chartered Logistics Limited's subsidiary, Chartered Comcare IFSC Limited, received regulatory approval from IFSCA to commence business as a Finance Company at GIFT City, Gujarat. The approval includes operating as a ship leasing entity. This license enables the company to expand its financial and logistics service footprint within the IFSC framework.
Master Components Limited received a 'No Objection Certificate' from the National Stock Exchange for its merger with Master Moulds Private Limited. The approval, valid for six months, allows the company to proceed with the scheme filing before NCLT. This marks a key regulatory milestone in the company's proposed corporate restructuring process.
Banganga Paper Industries Limited has received approval from BSE Limited to change its name to Asgard Alcobev Limited. The change is effective from April 17, 2026, on the exchange's trading system under the new scrip ID 'ASGARD'. This rebranding marks a significant corporate milestone for the company.
Kirloskar Industries Limited received approval from the National Stock Exchange of India (NSE) for a waiver of fines previously levied for non-compliance with Regulation 31 of SEBI Regulations. The waiver pertains to a delay in compliance for the quarter ended December 31, 2025.